top of page

We put science and patients first.

At Uniquity Bio, we develop innovative and needed medicines with an unparalleled blend of scientific rigor and operational agility — so that we can deliver powerful solutions, fast, to people living with immune-mediated diseases.

A proven team, backed by Blackstone

Uniquity Bio was built by a leadership team with decades of experience in immunology and inflammation and a successful track record advancing clinical programs through development to commercialization. As a Blackstone Life Sciences portfolio company, we have the expertise and committed capital to support a valuable and dynamic pipeline of high-potential medicines along with a range of partnership structures for maximum value.

Meet Our Team
Meet Our Leaders

Our highly-credentialed team has the vision and experience — in global pharma, biotech, and research — to identify and advance medicines that will make a difference in immunology and inflammation.

Partner with Us

With clinical expertise, committed capital, and agile operations, Uniquity Bio is a reliable partner to advance and optimize high-quality assets through partnership options including acquisitions, licensing, joint ventures, and buyback rights.

About Us

Our trusted strategy for clinical drug development delivers meaningful, best-in-class products to patients and industry partners while creating value for investors.


May 15, 2024

Blackstone Life Sciences Launches Uniquity Bio to Develop Novel Medicines in Immunology & Inflammation

Blackstone Commits $300M in Financing

Nexstone Immunology Hero Image 1.jpg


We’re actively expanding our immunology and inflammation pipeline, with a laser focus on therapeutics for indications with limited or no treatment options.


Our first lead asset is solrikitug, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), in which we aim to deliver best-in-class efficacy in several critical respiratory and gastrointestinal (GI) indications, including chronic obstructive pulmonary disease (COPD) and asthma.

bottom of page